Dr. AniBalmanoukian is a hematology/oncology specialist affiliated with Marina del Rey Hospital. She received her medical degree from the New York Medical College School of Medicine and also has a Bachelor of Science degree in the field of Psychological Science from the University of California, Los Angeles. Certified by the CA State Medical Board she is also leading the Lung Cancer Clinical Program at The Angeles Clinic and Research Institute.

Insurance Accepted

Languages Spoken

  • Armenian
  • English

Education & Training

Medical Degree

New York Medical College


The John Hopkins Hospital, Baltimore, MD


The John Hopkins Hospital, Baltimore, MD


The John Hopkins Hospital, Baltimore, MD

Publications & Media

  • Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.

  • Outcomes of African American (AA) versus caucasian (CA) women with triple-negative (TN) breast cancer following preoperative anthracycline and taxane-based chemotherapy.

  • Clinical use of personalized molecular biomarkers in patients with glioblastoma.

  • Effect of standard therapy on lymphocyte subsets and cytokines in newly diagnosed high-grade gliomas (HGG).

  • Effect of chemoradiation-related lymphopenia on survival in patients with unresectable, locally advanced pancreatic adenocarcinoma

  • Effect of treatment-related lymphopenia on survival in newly diagnosed patients with resected adenocarcinoma of the pancreas.

  • Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.

  • Managing the patient with borderline resectable lung cancer.

  • African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.

  • The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas.

  • Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors.

  • Sustained CD4(+) T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide.